A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

NCT00965432 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Fragile X Syndrome

Interventions

DRUG: STX107

Sponsor

Seaside Therapeutics, Inc.

Collaborators

[object Object]